CN115537356B - Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof - Google Patents

Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof Download PDF

Info

Publication number
CN115537356B
CN115537356B CN202211241806.0A CN202211241806A CN115537356B CN 115537356 B CN115537356 B CN 115537356B CN 202211241806 A CN202211241806 A CN 202211241806A CN 115537356 B CN115537356 B CN 115537356B
Authority
CN
China
Prior art keywords
probiotic
blood pressure
preventing
lactobacillus
efficacy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211241806.0A
Other languages
Chinese (zh)
Other versions
CN115537356A (en
Inventor
方曙光
王命荣
郭晓娟
汪欣
朱建国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
WeCare Probiotics Co Ltd
Original Assignee
WeCare Probiotics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by WeCare Probiotics Co Ltd filed Critical WeCare Probiotics Co Ltd
Priority to CN202211241806.0A priority Critical patent/CN115537356B/en
Publication of CN115537356A publication Critical patent/CN115537356A/en
Application granted granted Critical
Publication of CN115537356B publication Critical patent/CN115537356B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/245—Lactobacillus casei
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • C12R2001/25—Lactobacillus plantarum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The invention provides a compound probiotic with an effect of preventing or relieving blood pressure rise, a preparation method and application thereof, wherein probiotics in the compound probiotic comprise lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain and lactobacillus helveticus Lactobacillus helveticus LH strain. The three strains are creatively compounded to obtain the compound probiotic, and the components are matched and synergistic mutually, so that the compound probiotic has more remarkable effect of relieving the rise of blood pressure compared with a single strain. The compound probiotic agent can be further applied to the preparation of foods, health products or medicines.

Description

Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof
Technical Field
The invention belongs to the technical field of probiotics, and relates to a composite probiotic with an effect of preventing or relieving blood pressure rise, and a preparation method and application thereof.
Background
Hypertension is the most common cardiovascular disease found so far, and is also the main pathogenic mechanism of diseases such as sudden cerebral death, coronary heart disease, renal failure and the like, so that the risk of cardiovascular system diseases can be reduced by preventing and treating hypertension. At present, people pay more attention to research, prevention and treatment of hypertension, and the research of multifunctional food in the aspect of reducing blood pressure has important effect. Hypertension has been shown to be caused by a variety of causes, including neurological, genetic, mental, endocrine, and Angiotensin Converting Enzyme (ACE), among others.
The mechanism of blood pressure lowering in humans is generally mediated by a group of antagonistic systems, the renin angiotensin system and the kinin-kinin regenerating enzyme system. In a human body, after kidney elements flow into plasma, carrying out a hydrolysis process on angiotensinogen in the plasma to obtain capillary tensional I (AT 1); because the function of angiotensin converting enzyme ACE converts capillary tensional I into capillary tensional II (Ang II), capillary tensional II can improve the contractility of heart and can also lead to the increase of high pressure caused by the contraction of vascular smooth muscle. At the same time, ACE has also been involved in regulating the kallikrein system, resulting in the conversion of bradykinin with bradykinin function to inactive sustained and controlled release peptides. ACE acts synergistically on both systems, causing an increase in high pressure in the human body. To achieve a drop in blood pressure, ACE activity must be inhibited.
ACE also directly activates adrenal cortex to release aldosterone, and its main action mechanism is to increase extracellular fluid capacity and human plasma volume by reducing excretion of salt and water from kidney, thereby increasing venous return current and indirectly inducing hypertension. The protease produced by lactobacillus plantarum shears part of the activity fragments and simultaneously releases the activity fragments, the part of the activity fragments are fused with the activity center of ACE, the ACE activity is competitively controlled, and the angiotensin I can not be converted into angiotensin II, so that the purpose of reducing blood pressure is realized.
The primary antihypertensive drugs proposed at present are five major classes of beta receptor blockers, diuretics, capillary tensioners invertase inhibitors (ACEI), calcium channel blockers, capillary tensioners ii two-receptor binding inhibitors. Each medicine has the characteristics and certain side effects.
ACEI has certain curative effect on patients with hypertension in various periods, does not cause heart rate increase or interfere with the regulation of vascular smooth muscle by parasympathetic nervous system, but the synthesized ACEI has main adverse effects of easily generating proteinuria, rash, leucopenia and the like. Treatment with antihypertensive drugs is responsible for increased incidence of coronary heart disease; changes in metabolism during drug therapy can be affected, particularly potentially detrimental effects on glucose, fat and uric acid metabolism; the probability of cerebral blood reduction caused by the blood pressure reduction caused by the drug treatment is increased, and vision disorder, cerebral ischemia, ischemic cerebral apoplexy and the like can be caused. Thus, there is increasing interest in treating hypertension by non-drug therapy.
Disclosure of Invention
Aiming at the defects of the prior art, the invention aims to provide a compound probiotic with the efficacy of preventing or relieving the rise of blood pressure, and a preparation method and application thereof.
In order to achieve the aim of the invention, the invention adopts the following technical scheme:
in a first aspect, the invention provides a composite probiotic with the effect of preventing or alleviating elevated blood pressure, wherein probiotics in the composite probiotic comprise lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain 89 and lactobacillus helveticus Lactobacillus helveticus LH strain 76.
The invention creatively compounds three strains of lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain and lactobacillus helveticus Lactobacillus helveticus LH strain to obtain the compound probiotic, and all the components are matched and synergistic mutually.
Preferably, the ratio of the viable count of the lactobacillus plantarum Lactobacillus plantarum Lp strain, the lactobacillus casei Lactobacillus casei LC strain and the lactobacillus helveticus Lactobacillus helveticus LH strain is (10-20): 5-10): 15-30.
The specific point values in (10-20) may be selected from 10, 12, 14, 15, 16, 17, 18, 20, etc.
The specific point values in (5-10) may be selected from 5, 6, 7, 8, 9, 10, etc.
The specific point values in (15-30) may be selected from 15, 17, 18, 20, 22, 25, 28, 30, etc.
Other specific point values in the numerical ranges are selectable, and will not be described in detail herein.
Preferably, the composite probiotic agent further comprises a protective agent.
Preferably, the protective agent comprises skim milk and/or skim milk powder.
Preferably, the composite probiotic agent further comprises a carrier.
Preferably, the carrier comprises any one or a combination of at least two of microcrystalline cellulose, inulin, magnesium stearate, sugar alcohols or starch.
Preferably, the carrier is a combination of microcrystalline cellulose, sugar alcohol, inulin and starch.
The combination of microcrystalline cellulose, sugar alcohol, inulin and starch is more preferred for the carrier because in this combination the complex probiotic is more stable and can maintain the product morphology and mouthfeel for a long period of time.
Preferably, the sugar alcohol is selected from any one or a combination of at least two of xylitol, maltitol, erythritol, sorbitol, isomalt or lactitol.
Preferably, the starch is selected from any one or a combination of at least two of acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate or acetylated distarch adipate.
The formulation of the composite probiotics can be freeze-dried powder, tablets, capsules, solutions, emulsions and the like.
In a second aspect, the present invention provides a method for preparing the composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to the first aspect, the method comprising:
(1) Mixing lactobacillus plantarum Lactobacillus plantarum Lp, lactobacillus casei Lactobacillus casei LC and lactobacillus helveticus Lactobacillus helveticus LH76 with a protective agent according to a proportion to obtain an emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier, and performing micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic with the effect of preventing or relieving the rise of blood pressure.
In a third aspect, the present invention provides the use of a complex probiotic with efficacy in preventing or alleviating elevated blood pressure according to the first aspect in the manufacture of a medicament.
In a fourth aspect, the invention provides a probiotic beverage, which is prepared from the following raw materials in percentage by mass: the compound probiotics of the first aspect are 0.01-10%, prebiotics 0.01-5%, stabilizing agent 0.1-1%, sweetener 0.01-0.05% and water.
The mass percentage of the composite probiotics can be selected from 0.01%, 0.1%, 1%, 2%, 3%, 5%, 7%, 8%, 10% and the like.
The mass percentage of the prebiotics can be selected from 0.01%, 0.1%, 0.5%, 1%, 2%, 3%, 3.5%, 4%, 5% and the like.
The mass percentage of the stabilizer can be selected from 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 1% and the like.
The mass percentage of the sweetener can be selected from 0.01%, 0.02%, 0.03%, 0.04%, 0.05% and the like.
Other specific point values in the numerical ranges are selectable, and will not be described in detail herein.
Preferably, the prebiotic is selected from any one or a combination of at least two of stachyose, fructo-oligosaccharide, isomaltooligosaccharide or galactooligosaccharide.
Preferably, the sweetener is selected from any one or a combination of at least two of acesulfame potassium, aspartame, sucralose or steviol glycosides.
Preferably, the stabilizer is selected from any one or a combination of at least two of sodium carboxymethyl cellulose, pectin, soybean polysaccharide, agar or sodium caseinate; preferably a combination of pectin and soy polysaccharide.
Compared with the prior art, the invention has the following beneficial effects:
the invention creatively compounds three strains of lactobacillus plantarum Lactobacillus plantarum Lp strain, lactobacillus casei Lactobacillus casei LC strain and lactobacillus helveticus Lactobacillus helveticus LH strain to obtain the compound probiotic, and all the components are matched and synergistic mutually.
Detailed Description
In order to further describe the technical means adopted by the present invention and the effects thereof, the following describes the technical scheme of the present invention in combination with the preferred embodiments of the present invention, but the present invention is not limited to the scope of the embodiments.
(1) The lactobacillus plantarum Lp05 is lactobacillus plantarum Lactobacillus plantarum Lp strain, the preservation unit is China general microbiological culture Collection center, the preservation number is CGMCC No.23547, the preservation date is 2021 and 10 and 09 days, and the preservation address is North Chen and West road No.1 and 3 in the Korean region of Beijing city.
(2) The lactobacillus helveticus LH76 is lactobacillus helveticus Lactobacillus helveticus LH strain, the preservation unit is China general microbiological culture Collection center (CGMCC) No.18796, the preservation date is 2019, 11 months and 4 days, and the preservation address is North Chen Xili No.1, 3 in the Korean region of Beijing city.
(3) The lactobacillus casei LC89 is lactobacillus casei Lactobacillus casei LC strain, the preservation unit is China general microbiological culture Collection center, the preservation number is CGMCC No.15409, the preservation date is 2018, 03 and 05, and the preservation address is North Chen West Lu No.1 of the Korean region of Beijing city.
MRS solid medium as described below: weighing peptone 10g, beef extract 10g, glucose 20 g, lactose 10g, yeast extract 5 g, diammonium hydrogen citrate 2 g, K 2 PO 4 ·3H 2 O 2 g、MgSO 4 ·7H 2 O 0.6 g、MnSO 4 0.01 g, agar 20 g and L-cysteine 1 g, dissolving with deionized water, adding 1 mL Tween 80, fixing volume to 1L, sterilizing, cooling, and pouring into sterilized culture dish.
MRS liquid medium is as follows: weighing peptone 10g, beef extract 10g, glucose 20 g, lactose 10g, yeast extract 5 g, diammonium hydrogen citrate 2 g, K 2 PO 4 ·3H 2 O 2 g、MgSO 4 ·7H 2 O 0.6 g、MnSO 4 0.01 g and L-cysteine 1 g are dissolved by deionized water, then 1 mL Tween 80 is added, the volume is fixed to 1L, and after sterilization and cooling, the mixture is poured into a sterilized culture dish for standby.
The following lactobacillus plantarum Lp05, lactobacillus helveticus LH76, lactobacillus casei LC89 bacterial suspensions are involved: inoculating the bacteria into MRS liquid culture medium, culturing at 38deg.C for 18h for activation, and continuously activating for 2 times to obtain activating solution; inoculating the activating solution into MRS liquid culture medium according to the inoculum size of 2% (v/v), and culturing at 38deg.C for 18h to obtain bacterial solution; centrifuging the bacterial liquid at 8000g for 10min, collecting supernatant, and filtering with 0.22 μm sterile filter membrane to obtain supernatant; and (5) re-suspending the thalli by using PBS to obtain the microbial inoculum.
The sources of the components in the following examples are shown below:
example 1
This example demonstrates gastric acid resistance of three bacteria, as follows:
(1) Preparing artificial gastric juice:
the artificial gastric juice contains 0.20% of NaCl and 0.30% of pepsin by mass fraction, the pH is regulated to 3.0 by using HCl, and the artificial gastric juice is filtered for sterilization for standby.
(2) Gastric acid resistance test:
taking 1.0 mL Lactobacillus plantarum Lp05, lactobacillus helveticus LH76 and Lactobacillus casei LC89 suspension (1×10 concentration) 9 CFU/mL, the concentration of bacterial liquid is measured by the method in national standard food safety national Standard microbiological detection of lactic acid bacteria of GB4789.35-2016, respectively, and is mixed with 9.0 mL of artificial gastric juice with pH of 3.0, and then anaerobic stationary culture is carried out at 37 ℃, sampling is carried out after 0h and 3h treatment are started, the viable count is measured by a pouring culture method, and the survival rate is calculated, wherein the formula is as follows:
survival (%) =n1/n0×100%,
wherein, N1: viable count after 3 hours of artificial gastric juice treatment; n0: viable count of 0 h. The test results are shown in Table 1.
TABLE 1
As can be seen from the data in table 1: the probiotics disclosed by the invention have good gastric acid resistance and good acid resistance, and conditions are created for preparing products for preventing or relieving hypertension from rising.
Example 2
The example demonstrates the bile salt resistance of three bacteria, the steps being as follows:
the bacterial liquid content is adjusted to 10 8 centrifuging cfu/ml at 3000r/min for 10min, removing supernatant, adding sterilized MRS liquid culture medium containing 0.3% bile salt to the centrifuged thallus, shaking uniformly, placing into a constant temperature incubator at 37 deg.C, continuously taking samples within 0h and 3h, diluting with sterilized PBS, coating on MRS plate, culturing at 37 deg.C for 36h, and counting. The formula is as follows:
survival (%) =n1/n0×100%,
wherein, N1: viable count after 3 hours of treatment; n0: viable count of 0 h. The test results are shown in Table 2.
TABLE 2
As can be seen from the data in table 2: the probiotics provided by the invention have good bile salt resistance, and good bile salt resistance creates conditions for preparing products for preventing or relieving hypertension.
Example 3
The embodiment provides a compound probiotic with the effect of preventing or relieving the rise of blood pressure, and the preparation method comprises the following steps:
(1) Mixing 40 parts of bacterial powder (the viable count of lactobacillus plantarum Lactobacillus plantarum Lp, lactobacillus casei Lactobacillus casei LC89 and lactobacillus helveticus Lactobacillus helveticus LH76 is 15:5:20) with 10 parts of skim milk to obtain emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier (5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, 10 parts of inulin and 10 parts of starch), and performing micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic with the effect of preventing or relieving the rise of blood pressure.
Example 4
The preparation method of the compound probiotic with the effect of preventing or relieving the rise of blood pressure is different from that of the embodiment 3 only in that 40 parts of bacterial powder is lactobacillus plantarum Lactobacillus plantarum Lp05 and lactobacillus casei Lactobacillus casei LC89 with the viable count of 15:5. The other steps remain unchanged.
Example 5
The preparation method of the compound probiotic with the effect of preventing or relieving the rise of blood pressure is different from that of the embodiment 3 only in that 40 parts of bacterial powder is lactobacillus plantarum Lactobacillus plantarum Lp05 and lactobacillus helveticus Lactobacillus helveticus LH with the viable count of 15:20. The other steps remain unchanged.
Example 6
The preparation method of the compound probiotic with the effect of preventing or relieving the rise of blood pressure is different from that of the embodiment 3 only in that 40 parts of bacterial powder is lactobacillus casei Lactobacillus casei LC89 and lactobacillus helveticus Lactobacillus helveticus LH with the viable count of 5:20. The other steps remain unchanged.
Example 7
The present example provides a compound probiotic with efficacy of preventing or alleviating the rise of blood pressure, and the preparation method differs from example 3 only in that the carrier in step (2) is 10 parts of sugar alcohol, 10 parts of inulin and 10 parts of starch. The other steps remain unchanged.
Example 8
The present embodiment provides a compound probiotic with an effect of preventing or alleviating an increase in blood pressure, and the preparation method is different from embodiment 3 only in that the carrier in step (2) is 10 parts of microcrystalline cellulose, 10 parts of inulin and 10 parts of starch. The other steps remain unchanged.
Example 9
The present embodiment provides a compound probiotic with an effect of preventing or alleviating an increase in blood pressure, and the preparation method is different from embodiment 3 only in that the carrier in step (2) is 5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, and 20 parts of starch. The other steps remain unchanged.
Example 10
The present embodiment provides a compound probiotic with an effect of preventing or alleviating an increase in blood pressure, and the preparation method is different from embodiment 3 only in that the carrier in step (2) is 5 parts of microcrystalline cellulose, 5 parts of sugar alcohol, and 20 parts of inulin. The other steps remain unchanged.
Test example 1
And (3) measuring the antihypertensive effect of the composite probiotics:
(1) Experimental animals: male essential Severe Hypertension Rats (SHR), about eight weeks old, average weight 170-210 g, supplied by Shanghai laboratory animal management center, proc, animal eligibility number: shanghai Hui He pattern 152. Male SD rats, 8 weeks old, weighing 170-210 g, supplied by the experimental mammalian management center in Shanghai, national academy of sciences, animals meeting qualification number: shanghai Hui He pattern 152. The indoor illumination of animals is 12h illumination, the indoor ventilation and air conditioning equipment is normal, the room temperature is controlled at 22+/-3 ℃, and the relative humidity is about 50-70%.
(2) The experimental animals are adapted to the environment for 7 days, and after the blood pressure is stabilized, continuous gastric lavage is started, and the experimental gastric lavage time is 9:00 am every day. 40 SHR rats were randomly divided into 5 groups: model control, example 3, example 4, example 5, example 6; 8 SD rats were used as SD control group. Comparative group is filled with normal saline, and example group is filled with 10 mg/kg of the composite probiotics prepared in each example.
(3) The rats were tested after stable depressurization and pressure test, the pre-dosing depressurization and then the intragastric administration treatment were measured for the rats, the intragastric administration treatment was performed once daily for 4 weeks, the high pressure of the SHR tail artery was measured with a BP-98A intelligent noninvasive sphygmomanometer and repeated three times, the average value was obtained, and the measured value was displayed as the average value. As shown in table 3.
TABLE 3 Table 3
From the data results in table 3, it can be seen that: the composite probiotics related by the invention has remarkable effect of relieving the rise of blood pressure, and the lactobacillus plantarum Lp05 strain, the lactobacillus casei LC89 strain and the lactobacillus helveticus LH76 strain in the composite probiotics have synergistic effect on the effects.
Application example 1
The application example provides a probiotic beverage, wherein the preparation raw materials of the probiotic beverage comprise the following components in percentage by mass: 5% of the compound probiotics prepared in the embodiment 3, 5% of fructo-oligosaccharide, 0.5% of pectin, 0.5% of soybean polysaccharide, 0.04% of sucralose and the balance of water.
Application examples 2 to 8
The application example provides seven probiotic beverages, and the preparation raw materials of the probiotic beverages are different from the application example 1 only in that the compound probiotic prepared in the example 3 is replaced by the compound probiotic prepared in the examples 4-10 with equal amount respectively, and other raw materials and contents are kept unchanged.
Test example 2
Testing the stability of the probiotic beverage:
the probiotic beverages of application examples 1-8 were stored refrigerated at 4 ℃ for 21 days and the tissue state was visually observed. The products of each group are scored, the layering phenomenon is obvious in 1 division, the layering phenomenon is not obvious in 2 division, and the layering phenomenon is not obvious in 3 division, so that the products are very uniform. The results are shown in Table 4.
TABLE 4 Table 4
From the results in Table 4, it can be seen that: the beverage product prepared by using the composite probiotic provided by the invention has good stability, wherein the composition mode of the carrier material in the composite probiotic obviously influences the stability of the beverage product.
The applicant states that the present invention is described by the above examples as a composite probiotic agent having an effect of preventing or alleviating an increase in blood pressure, and a preparation method and application thereof, but the present invention is not limited to the above examples, i.e., it does not mean that the present invention must be practiced depending on the above examples. It should be apparent to those skilled in the art that any modification of the present invention, equivalent substitution of raw materials for the product of the present invention, addition of auxiliary components, selection of specific modes, etc., falls within the scope of the present invention and the scope of disclosure.
The preferred embodiments of the present invention have been described in detail above, but the present invention is not limited to the specific details of the above embodiments, and various simple modifications can be made to the technical solution of the present invention within the scope of the technical concept of the present invention, and all the simple modifications belong to the protection scope of the present invention.
In addition, the specific features described in the above embodiments may be combined in any suitable manner, and in order to avoid unnecessary repetition, various possible combinations are not described further.

Claims (16)

1. A compound probiotic with the effect of preventing or relieving the rise of blood pressure is characterized in that probiotics in the compound probiotic are prepared from lactobacillus plantarum with the preservation number of CGMCC No.23547Lactobacillus plantarum) Lp05 strain and lactobacillus casei with preservation number of CGMCC No.15409Lactobacillus casei) LC89 strain and Lactobacillus helveticus with preservation number of CGMCC No.18796Lactobacillus helveticus) LH76 strain.
2. The compound probiotic with the efficacy of preventing or relieving the elevation of blood pressure according to claim 1, wherein the lactobacillus plantarum Lactobacillus plantarum Lp05 Strain, lactobacillus caseiLactobacillus caseiLC89 strain and lactobacillus helveticusLactobacillus helveticus The ratio of the viable count of LH76 strain is (10-20): 5-10): 15-30.
3. The complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 1 or 2, characterized in that the complex probiotic further comprises a protective agent.
4. A complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 3, characterized in that the protective agent comprises skim milk and/or skim milk powder.
5. The composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 1, further comprising a carrier.
6. The composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 5, wherein the carrier comprises any one or a combination of at least two of microcrystalline cellulose, inulin, magnesium stearate, sugar alcohol or starch.
7. The complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 6, wherein the carrier is a combination of microcrystalline cellulose, sugar alcohol, inulin and starch.
8. The complex probiotics for preventing or alleviating elevated blood pressure according to claim 7, wherein said sugar alcohol is selected from any one or a combination of at least two of xylitol, maltitol, erythritol, sorbitol, isomalt or lactitol.
9. The composite probiotic with efficacy of preventing or alleviating elevated blood pressure according to claim 7, wherein the starch is selected from any one or a combination of at least two of acetate starch, sodium starch octenyl succinate, hydroxypropyl distarch phosphate, phosphate distarch, acid treated starch, oxidized hydroxypropyl starch, acetylated distarch phosphate or acetylated distarch adipate.
10. The method for producing a composite probiotic having an efficacy of preventing or alleviating an increase in blood pressure according to any one of claims 1 to 9, characterized by comprising:
(1) Lactobacillus plantarum is preparedLactobacillus plantarum Lp05, lactobacillus caseiLactobacillus caseiLC89 and Lactobacillus helveticusLactobacillus helveticus LH76 is mixed with a protective agent according to a proportion to obtain emulsion;
(2) Mixing the emulsion obtained in the step (1) with a carrier, and performing micro-embedding treatment to obtain an embedding mixture;
(3) And (3) carrying out electrostatic spray drying on the embedding mixture obtained in the step (2) to obtain the composite probiotic with the effect of preventing or relieving the rise of blood pressure.
11. Use of a complex probiotic with efficacy of preventing or alleviating elevated blood pressure according to any one of claims 1 to 9 in the manufacture of a medicament with efficacy of preventing or alleviating elevated blood pressure.
12. The probiotic beverage is characterized by comprising the following preparation raw materials in percentage by mass: the composite probiotic of any one of claims 1-9, 0.01-10%, prebiotics 0.01-5%, stabilizers 0.1-1%, sweeteners 0.01-0.05%, water.
13. The probiotic beverage according to claim 12, characterized in that the prebiotic is selected from any one or a combination of at least two of stachyose, fructo-oligosaccharides, isomaltooligosaccharides or galactooligosaccharides.
14. The probiotic beverage according to claim 12, characterized in that the sweetener is selected from any one or a combination of at least two of acesulfame k, aspartame, sucralose or steviol glycosides.
15. The probiotic beverage according to claim 12, characterized in that the stabilizer is selected from any one or a combination of at least two of sodium carboxymethyl cellulose, pectin, soy polysaccharide, agar or sodium caseinate.
16. The probiotic beverage according to claim 15, characterized in that the stabilizer is a combination of pectin and soy polysaccharide.
CN202211241806.0A 2022-10-11 2022-10-11 Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof Active CN115537356B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211241806.0A CN115537356B (en) 2022-10-11 2022-10-11 Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211241806.0A CN115537356B (en) 2022-10-11 2022-10-11 Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN115537356A CN115537356A (en) 2022-12-30
CN115537356B true CN115537356B (en) 2024-02-13

Family

ID=84733433

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211241806.0A Active CN115537356B (en) 2022-10-11 2022-10-11 Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN115537356B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116515684B (en) * 2023-03-29 2024-03-01 微康益生菌(苏州)股份有限公司 Probiotic agent for improving hyperphosphatemia and application thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008050269A (en) * 2006-08-22 2008-03-06 Gekkeikan Sake Co Ltd Oral ingestion material
CN110179120A (en) * 2018-02-22 2019-08-30 杨涵 A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia
CN113755357A (en) * 2020-06-04 2021-12-07 内蒙古伊利实业集团股份有限公司 Lactobacillus preparation and application thereof
CN114651984A (en) * 2022-03-30 2022-06-24 微康益生菌(苏州)股份有限公司 Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113430133B (en) * 2021-06-24 2023-06-23 微康益生菌(苏州)股份有限公司 Composite probiotics capable of relieving ulcerative colitis, preparation method and application thereof
CN113980878B (en) * 2021-12-29 2022-03-15 微康益生菌(苏州)股份有限公司 Lactobacillus plantarum for resisting helicobacter pylori infection and application thereof
CN114854643B (en) * 2022-06-02 2023-01-31 微康益生菌(苏州)股份有限公司 Culture medium for promoting lactobacillus and bifidobacterium to co-proliferate and application thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008050269A (en) * 2006-08-22 2008-03-06 Gekkeikan Sake Co Ltd Oral ingestion material
CN110179120A (en) * 2018-02-22 2019-08-30 杨涵 A kind of compound diet of probiotics pectase corn peptide improving immunity lower hyperlipidemia, hypertension, hyperglycemia
CN113755357A (en) * 2020-06-04 2021-12-07 内蒙古伊利实业集团股份有限公司 Lactobacillus preparation and application thereof
CN114651984A (en) * 2022-03-30 2022-06-24 微康益生菌(苏州)股份有限公司 Application of lactobacillus casei LC89 and microbial preparation containing same in preparation of product for relieving functional constipation

Also Published As

Publication number Publication date
CN115537356A (en) 2022-12-30

Similar Documents

Publication Publication Date Title
US11268064B2 (en) Lactobacillus rhamnosus RHT-3201 conjugated to polysaccharide polymer binder, and use thereof for prevention or treatment of atopic diseases
CN103648512B (en) The bacterium bacterial strain for belonging to Bifidobacterium for the treatment of hypercholesterolemia
CN115537356B (en) Composite probiotic with efficacy of preventing or relieving blood pressure rise as well as preparation method and application thereof
CN112370470A (en) Microecological preparation for reconstructing intestinal microecology
CN117106679B (en) Probiotic agent for relieving insulin resistance and application thereof
CN102429034A (en) Composite colostrum
AU2005247084A1 (en) Oral and/or topical compositions comprising prebiotics and sterols
EP3677273B1 (en) Bacteroides cellulosityticus for use in preventing and/or treating atherosclerosis and obesity
ES2357408T3 (en) SYMBOLIC COMPOSITION AND ITS MANUFACTURING PROCEDURE.
JP6261688B2 (en) QOL improvement or persistence agent
JP6072516B2 (en) Allergy improving agent
JP2021505609A (en) Use of BUTYRlBACTER INTERSTINI in the prevention and / or treatment of inflammation-related diseases
CN107158225A (en) A kind of Shengmai Yin composition and its preparation method and application
KR20040037011A (en) Food Composition Containing a Lactic Acid Bacteria
EP3677272B1 (en) Application of alistipes shahii in preparing a composition for preventing and/or treating lipid metabolism related diseases
WO2006000137A1 (en) Oral disintegrable tablet of notogingseng total sapoin and the preparation process thereof
CN104382002A (en) Maca tablet for alleviating fatigue
CN116211956A (en) Composition for regulating intestinal tract and/or improving obesity, preparation method, chewable tablet and application thereof
CN115226773A (en) Composite probiotic sleep-aiding solid beverage and preparation method thereof
WO2019035486A1 (en) Agent for suppressing spikes in blood glucose levels, method for producing food and agent for suppressing spikes in blood glucose level
WO2004113509A1 (en) Lactobacillus casei lc2w strain and its use in antihypertensive aspect
CN113558238A (en) Natto freeze-dried powder spina date seed solid beverage and preparation method thereof
CN112753775A (en) Anti-inflammation milk powder and preparation method thereof
CN108685981A (en) A kind of notoginseng-red sage capsule and preparation method thereof
CN103316013A (en) Aprepitant composition for injection

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant